BioCentury | Apr 27, 2015
Politics, Policy & Law

Speed trials

The 2014 West Africa Ebola outbreak is stimulating the fastest vaccine development efforts ever attempted, demonstrating the power of an emerging model that combines the expertise, capabilities and resources of experienced pharma companies, government biomedical...
BC Week In Review | Apr 6, 2015
Clinical News

RVSV-EBOV: Preliminary Phase II data

Preliminary data from >600 healthy volunteers in the Phase II portion of the double-blind, placebo-controlled, Liberian Phase II/III PREVAIL trial showed that a single injection of cAd-EBOZ or VSV-ZEBOV appears to be safe. The trial...
BC Week In Review | Apr 6, 2015
Clinical News

cAd-EBOZ: Preliminary Phase II data

Preliminary data from >600 healthy volunteers in the Phase II portion of the double-blind, placebo-controlled, Liberian Phase II/III PREVAIL trial showed that a single injection of cAd-EBOZ or VSV-ZEBOV appears to be safe. The trial...
BC Week In Review | Feb 23, 2015
Clinical News

RVSV-EBOV: Phase II/III started

The National Institute of Allergy and Infectious Diseases (NIAID) began the double-blind, placebo-controlled, Liberian Phase II/III PREVAIL trial to evaluate a single injection of cAd-EBOZ or VSV-ZEBOV in about 28,170 healthy volunteers. cAd-EBOZ is a...
BC Week In Review | Feb 23, 2015
Clinical News

cAd-EBOZ: Phase II/III started

The National Institute of Allergy and Infectious Diseases (NIAID) began the double-blind, placebo-controlled, Liberian Phase II/III PREVAIL trial to evaluate a single injection of cAd-EBOZ or VSV-ZEBOV in about 28,170 healthy volunteers. VSV-ZEBOV is a...
Items per page:
1 - 5 of 5